ABEO
Abeona Therapeutics Inc
NASDAQ: ABEO · HEALTHCARE · BIOTECHNOLOGY
$5.86
-6.19% today
Updated 2026-06-05
Market cap
$320.88M
P/E ratio
5.93
P/S ratio
22.15x
EPS (TTM)
$0.95
Dividend yield
—
52W range
$4 – $8
Volume
1.1M
WallStSmart proprietary scores
43
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+7.5
Quality
B+6.0
Profitability
B6.7
Valuation
B6/9
Piotroski F-Score
Moderate
-3.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$19.71
+236.35%
12-Month target
$4.42
-24.57%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 454.90% — above average
+ ROE 45.63% — strong efficiency
+ Debt/equity 0.16x — low leverage
Risks
- Altman Z -3.51 — distress zone
- Negative free cash flow $-20.74M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.41M | $3.50M | $0.00 | $5.82M | $14.54M |
| Net income | $-39.70M | $-54.19M | $-63.73M | $71.18M | $-17.07M |
| EPS | — | — | — | — | $0.95 |
| Free cash flow | $-43.61M | $-37.34M | $-58.46M | $-84.30M | $-20.74M |
| Profit margin | -2,807.36% | -1,548.23% | — | 1,223.08% | 454.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-22 | ALVINO, MARK | Sale | 6,500 | $5.46 |
| 2026-05-15 | CROMBEZ, ERIC | Sale | 26,143 | $5.53 |
| 2026-05-11 | VASANTHAVADA, MADHAV | Sale | 5,548 | $5.96 |
Peer comparison
Smart narrative
Abeona Therapeutics Inc trades at $5.86. representing a P/E of 5.93x trailing earnings. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -3.51, it sits in the distress. TTM revenue stands at $14.54M. with profit margins at 454.90%.
Frequently asked questions
What is Abeona Therapeutics Inc's stock price?
Abeona Therapeutics Inc (ABEO) trades at $5.86, on a P/E of 5.9x and a P/S of 22.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Abeona Therapeutics Inc overvalued?
Abeona Therapeutics Inc carries a Smart Value Score of 43/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Abeona Therapeutics Inc (ABEO)?
The 12-month analyst consensus target is $19.71, about 236.3% above the current $5.86. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Abeona Therapeutics Inc's revenue?
Abeona Therapeutics Inc's trailing twelve-month revenue is $14.54M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Abeona Therapeutics Inc's Altman Z-Score is -3.51, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio22.15x
ROE45.63%
Beta1.34
50D MA$5.23
200D MA$5.33
Shares out0.06B
Float0.04B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—